Global Secondary Progressive Multiple Sclerosis Drug Market Insights, Forecast to 2025

Table of Contents

1 Study Coverage

• 1.1 Secondary Progressive Multiple Sclerosis Drug Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate by Product
  • 1.4.2 Inebilizumab
  • 1.4.3 GLX-1112
  • 1.4.4 DC-TAB
  • 1.4.5 Etomoxir
  • 1.4.6 IB-MS
  • 1.4.7 Others
• 1.5 Market by End User
  • 1.5.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate by End User
  • 1.5.2 Hospital
  • 1.5.3 Clinic
  • 1.5.4 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size
  • 2.1.1 Global Secondary Progressive Multiple Sclerosis Drug Revenue 2014-2025
  • 2.1.2 Global Secondary Progressive Multiple Sclerosis Drug Sales 2014-2025
• 2.2 Secondary Progressive Multiple Sclerosis Drug Growth Rate by Regions
  • 2.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales by Regions
  • 2.2.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Secondary Progressive Multiple Sclerosis Drug Sales by Manufacturers
  • 3.1.1 Secondary Progressive Multiple Sclerosis Drug Sales by Manufacturers
  • 3.1.2 Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Manufacturers
  • 3.1.3 Global Secondary Progressive Multiple Sclerosis Drug Market Concentration Ratio (CR5 and HHI)
• 3.2 Secondary Progressive Multiple Sclerosis Drug Revenue by Manufacturers
  • 3.2.1 Secondary Progressive Multiple Sclerosis Drug Revenue by Manufacturers (2014-2019)
  • 3.2.2 Secondary Progressive Multiple Sclerosis Drug Revenue Share by Manufacturers (2014-2019)
• 3.3 Secondary Progressive Multiple Sclerosis Drug Price by Manufacturers
• 3.4 Secondary Progressive Multiple Sclerosis Drug Manufacturing Base Distribution, Product Types
  • 3.4.1 Secondary Progressive Multiple Sclerosis Drug Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Secondary Progressive Multiple Sclerosis Drug Product Type
  • 3.4.3 Date of International Manufacturers Enter into Secondary Progressive Multiple Sclerosis Drug Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Secondary Progressive Multiple Sclerosis Drug Sales by Product
• 4.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Product
• 4.3 Secondary Progressive Multiple Sclerosis Drug Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Secondary Progressive Multiple Sclerosis Drug Breakdown Data by End User

6 North America

• 6.1 North America Secondary Progressive Multiple Sclerosis Drug by Countries
  • 6.1.1 North America Secondary Progressive Multiple Sclerosis Drug Sales by Countries
  • 6.1.2 North America Secondary Progressive Multiple Sclerosis Drug Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Secondary Progressive Multiple Sclerosis Drug by Product
• 6.3 North America Secondary Progressive Multiple Sclerosis Drug by End User

7 Europe

• 7.1 Europe Secondary Progressive Multiple Sclerosis Drug by Countries
  • 7.1.1 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Countries
  • 7.1.2 Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Secondary Progressive Multiple Sclerosis Drug by Product
• 7.3 Europe Secondary Progressive Multiple Sclerosis Drug by End User

8 Asia Pacific

• 8.1 Asia Pacific Secondary Progressive Multiple Sclerosis Drug by Countries
  • 8.1.1 Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Countries
  • 8.1.2 Asia Pacific Secondary Progressive Multiple Sclerosis Drug Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Secondary Progressive Multiple Sclerosis Drug by Product
• 8.3 Asia Pacific Secondary Progressive Multiple Sclerosis Drug by End User

9 Central & South America

• 9.1 Central & South America Secondary Progressive Multiple Sclerosis Drug by Countries
  • 9.1.1 Central & South America Secondary Progressive Multiple Sclerosis Drug Sales by Countries
  • 9.1.2 Central & South America Secondary Progressive Multiple Sclerosis Drug Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Secondary Progressive Multiple Sclerosis Drug by Product
• 9.3 Central & South America Secondary Progressive Multiple Sclerosis Drug by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug by Countries
  • 10.1.1 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Countries
  • 10.1.2 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug by Product
• 10.3 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug by End User

11 Company Profiles

• 11.1 AB Science SA
  • 11.1.1 AB Science SA Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 AB Science SA Secondary Progressive Multiple Sclerosis Drug Products Offered
  • 11.1.5 AB Science SA Recent Development
• 11.2 Actelion Ltd
  • 11.2.1 Actelion Ltd Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Products Offered
  • 11.2.5 Actelion Ltd Recent Development
• 11.3 Biogen, Inc.
  • 11.3.1 Biogen, Inc. Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Products Offered
  • 11.3.5 Biogen, Inc. Recent Development
• 11.4 F. Hoffmann-La Roche Ltd.
  • 11.4.1 F. Hoffmann-La Roche Ltd. Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Products Offered
  • 11.4.5 F. Hoffmann-La Roche Ltd. Recent Development
• 11.5 Genzyme Corporation
  • 11.5.1 Genzyme Corporation Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Products Offered
  • 11.5.5 Genzyme Corporation Recent Development
• 11.6 Glialogix, Inc.
  • 11.6.1 Glialogix, Inc. Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Products Offered
  • 11.6.5 Glialogix, Inc. Recent Development
• 11.7 Immune Response BioPharma, Inc.
  • 11.7.1 Immune Response BioPharma, Inc. Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Products Offered
  • 11.7.5 Immune Response BioPharma, Inc. Recent Development
• 11.8 Innate Immunotherapeutics Ltd
  • 11.8.1 Innate Immunotherapeutics Ltd Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Products Offered
  • 11.8.5 Innate Immunotherapeutics Ltd Recent Development
• 11.9 Kyorin Pharmaceutical Co., Ltd.
  • 11.9.1 Kyorin Pharmaceutical Co., Ltd. Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Products Offered
  • 11.9.5 Kyorin Pharmaceutical Co., Ltd. Recent Development
• 11.10 Mallinckrodt Plc
  • 11.10.1 Mallinckrodt Plc Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Products Offered
  • 11.10.5 Mallinckrodt Plc Recent Development
• 11.11 MedDay SA
• 11.12 MedImmune, LLC
• 11.13 Merck KGaA
• 11.14 Meta-IQ ApS
• 11.15 Novartis AG
• 11.16 Opexa Therapeutics, Inc.
• 11.17 Xenetic Biosciences (UK) Limited

12 Future Forecast

• 12.1 Secondary Progressive Multiple Sclerosis Drug Market Forecast by Regions
  • 12.1.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Regions 2019-2025
• 12.2 Secondary Progressive Multiple Sclerosis Drug Market Forecast by Product
  • 12.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Product 2019-2025
  • 12.2.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Product 2019-2025
• 12.3 Secondary Progressive Multiple Sclerosis Drug Market Forecast by End User
• 12.4 North America Secondary Progressive Multiple Sclerosis Drug Forecast
• 12.5 Europe Secondary Progressive Multiple Sclerosis Drug Forecast
• 12.6 Asia Pacific Secondary Progressive Multiple Sclerosis Drug Forecast
• 12.7 Central & South America Secondary Progressive Multiple Sclerosis Drug Forecast
• 12.8 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Secondary Progressive Multiple Sclerosis Drug Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details